Please login to the form below

Not currently logged in
Email:
Password:

Hydra Biosciences and Pfizer sign global R&D novel ion-channel agreement

Hydra Biosciences signs a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist products for pain

Hydra Biosciences has signed a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist product candidates for pain.

Per the agreement, US-based Hydra will receive upfront and success-based development milestone payments of USD 195m for the first developed product launched and more for additional approved indications.

Pfizer will fund all R&D under the agreement and will receive exclusive access to Hydra's current TRPV3 patents as well as an exclusive license to commercialise any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.

Recent research on Transient Receptor Potential (TRP) antagonists indicates that they may act as multimodal signal integrators. Since TRP channels are only distantly related to voltage gated channels and homology among TRP family members is quite low, it is anticipated that specific and selective modulators may be more readily identified in this family than in other ion channel groups, limiting the potential for off-target effects, which have proven problematic in other ion channel families, such as Vioxx (rofecoxib) and other COX-2 inhibitors.

30th July 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....